Legal & General Group
GLUE icon

Legal & General Group’s Monte Rosa Therapeutics GLUE Stock Holding History

Legal & General Group’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$977K Buy
40,376
+16,057
+66% +$303K ﹤0.01% 2209
2026
Q1 		$400K Buy
24,319
+20,074
+473% +$384K ﹤0.01% 2412
2025
Q4 		$66.6K Hold
4,245
– – ﹤0.01% 2675
2025
Q3 		$31.5K Hold
4,245
– – ﹤0.01% 2871
2025
Q2 		$19.1K Buy
4,245
+648
+18% +$2.89K ﹤0.01% 3020
2025
Q1 		$16.7K Hold
3,597
– – ﹤0.01% 3010
2024
Q4 		$25K Sell
3,597
-12,962
-78% -$97.3K ﹤0.01% 2952
2024
Q3 		$87.8K Buy
16,559
+756
+5% +$3.82K ﹤0.01% 2738
2024
Q2 		$59.1K Hold
15,803
– – ﹤0.01% 2774
2024
Q1 		$111K Sell
15,803
-4,365
-22% -$25.9K ﹤0.01% 2728
2023
Q4 		$114K Sell
20,168
-14,457
-42% -$56.7K ﹤0.01% 2753
2023
Q3 		$166K Buy
34,625
+6,469
+23% +$41.6K ﹤0.01% 2757
2023
Q2 		$193K Buy
28,156
+19,937
+243% +$129K ﹤0.01% 2741
2023
Q1 		$64K Buy
8,219
+781
+11% +$5.43K ﹤0.01% 2837
2022
Q4 		$56.6K Buy
7,438
+384
+5% +$3.2K ﹤0.01% 2932
2022
Q3 		$57K Buy
7,054
+130
+2% +$1.19K ﹤0.01% 2946
2022
Q2 		$67K Buy
6,924
+1,931
+39% +$19.4K ﹤0.01% 2946
2022
Q1 		$70K Buy
4,993
+1,676
+51% +$23.3K ﹤0.01% 2940
2021
Q4 		$68K Buy
3,317
+2,235
+207% +$46.8K ﹤0.01% 2978
2021
Q3 		$24K Sell
1,082
-1,918
-64% -$55K ﹤0.01% 3212
2021
Q2 		$69K Buy
+3,000
New +$61.1K ﹤0.01% 2853

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Legal & General Group's GLUE Position: Q2 2026 in Review

Legal & General Group increased its Monte Rosa Therapeutics (GLUE) stake by 66% in Q2 2026, buying an estimated $303K and bringing the position to 40,376 shares worth $977K. The position accounts for ﹤0.01% of the portfolio, ranked #2209.

Legal & General Group first reported a position in GLUE in Q2 2021 and has held it in 21 quarters since. 192 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Legal & General Group held 40,376 shares of Monte Rosa Therapeutics worth $977K as of Q2 2026.
  • Legal & General Group bought 16,057 Monte Rosa Therapeutics shares in Q2 2026, an estimated $303K.
  • Monte Rosa Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #2209 holding.
  • Legal & General Group first reported a position in Monte Rosa Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • 192 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.